IBCSG 30-04 (MA.27)

  • A randomized phase III trial of exemestane vs. anastrozole in postmenopausal women with receptor positive primary breast cancer

  • Study Chair
    IBCSG: Dr. Manuela Rabaglio, Berne, Switzerland
    NCIC CTG: Dr. Paul Goss, Boston, USA

    Statistician
    Judy-Anne Chapman

    Director of the Data Management Center
    Holly Shaw

    IBCSG Data Management Center/FSTRF
    4033 Maple Road
    Amherst, New York 14226 USA
    Phone: +1 716 834 0900
    Fax: +1 716 833 3990
    Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

    Date of Activation
    April 12, 2005

    Date of Closure
    December 15, 2006

    Targeted Accrual
    6840 patients

    Final Accrual
    7576 patients

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login